188 related articles for article (PubMed ID: 17914440)
1. Vaccine immunopotentiators of the future.
Schijns VE; Degen WG
Clin Pharmacol Ther; 2007 Dec; 82(6):750-5. PubMed ID: 17914440
[TBL] [Abstract][Full Text] [Related]
2. Immunology of vaccine adjuvants.
Ribeiro CM; Schijns VE
Methods Mol Biol; 2010; 626():1-14. PubMed ID: 20099117
[TBL] [Abstract][Full Text] [Related]
3. Aluminium adjuvants--in retrospect and prospect.
Lindblad EB
Vaccine; 2004 Sep; 22(27-28):3658-68. PubMed ID: 15315845
[TBL] [Abstract][Full Text] [Related]
4. Vaccine adjuvant technology: from mechanistic concepts to practical applications.
Degen WG; Jansen T; Schijns VE
Expert Rev Vaccines; 2003 Apr; 2(2):327-35. PubMed ID: 12899582
[TBL] [Abstract][Full Text] [Related]
5. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators.
Nordly P; Madsen HB; Nielsen HM; Foged C
Expert Opin Drug Deliv; 2009 Jul; 6(7):657-72. PubMed ID: 19538037
[TBL] [Abstract][Full Text] [Related]
6. European union regulatory developments for new vaccine adjuvants and delivery systems.
Sesardic D; Dobbelaer R
Vaccine; 2004 Jun; 22(19):2452-6. PubMed ID: 15193409
[TBL] [Abstract][Full Text] [Related]
7. [Adjuvants for human vaccines].
Bröker M; Beyer C
Pharm Unserer Zeit; 2008; 37(1):42-51. PubMed ID: 18081081
[No Abstract] [Full Text] [Related]
8. The perfect mix: recent progress in adjuvant research.
Guy B
Nat Rev Microbiol; 2007 Jul; 5(7):505-17. PubMed ID: 17558426
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the adjuvanticity of aluminum salts and their combination in hepatitis B recombinant protein vaccine in assessed mice.
Mahboubi A; Fazeli MR; Dinarvand R; Samadi N; Sharifzadeh M; Ilka H; Azadi S; Soleimanian R; Kalkouei H; Hajikhanmirzaei R; Valadkhani M
Iran J Immunol; 2008 Sep; 5(3):163-70. PubMed ID: 18791283
[TBL] [Abstract][Full Text] [Related]
10. Particulate delivery systems for animal vaccines.
Scheerlinck JP; Greenwood DL
Methods; 2006 Sep; 40(1):118-24. PubMed ID: 16997719
[TBL] [Abstract][Full Text] [Related]
11. Nano- and microparticles as adjuvants in vaccine design: success and failure is related to host natural antibodies.
Sinyakov MS; Dror M; Lublin-Tennenbaum T; Salzberg S; Margel S; Avtalion RR
Vaccine; 2006 Oct; 24(42-43):6534-41. PubMed ID: 16842893
[TBL] [Abstract][Full Text] [Related]
12. Survey of human-use adjuvants.
Kenney RT; Edelman R
Expert Rev Vaccines; 2003 Apr; 2(2):167-88. PubMed ID: 12899569
[TBL] [Abstract][Full Text] [Related]
13. Adjuvants for human vaccines--current status, problems and future prospects.
Gupta RK; Siber GR
Vaccine; 1995 Oct; 13(14):1263-76. PubMed ID: 8585280
[TBL] [Abstract][Full Text] [Related]
14. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
[TBL] [Abstract][Full Text] [Related]
15. Preformulation studies--The next advance in aluminum adjuvant-containing vaccines.
Hem SL; HogenEsch H; Middaugh CR; Volkin DB
Vaccine; 2010 Jul; 28(31):4868-70. PubMed ID: 20488265
[No Abstract] [Full Text] [Related]
16. Biomaterials as vaccine adjuvants.
Jones KS
Biotechnol Prog; 2008; 24(4):807-14. PubMed ID: 19194892
[TBL] [Abstract][Full Text] [Related]
17. Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles.
Malyala P; O'Hagan DT; Singh M
Adv Drug Deliv Rev; 2009 Mar; 61(3):218-25. PubMed ID: 19168103
[TBL] [Abstract][Full Text] [Related]
18. Vaccine adjuvants revisited.
Aguilar JC; Rodríguez EG
Vaccine; 2007 May; 25(19):3752-62. PubMed ID: 17336431
[TBL] [Abstract][Full Text] [Related]
19. Influenza A (H5N1) pandemic prototype vaccine Fluval.
Vajo Z
Expert Rev Vaccines; 2009 May; 8(5):619-24. PubMed ID: 19397418
[TBL] [Abstract][Full Text] [Related]
20. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation.
Hem SL; Hogenesch H
Expert Rev Vaccines; 2007 Oct; 6(5):685-98. PubMed ID: 17931150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
